Montelukast Sodium Market - By Product Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline) Dosage Form (Tablets, Oral Solutions), Application (Asthma, Allergic Rhinitis, Urticaria), Distribution Channel – Global Forecast (2024 – 2032)

Montelukast Sodium Market Size

Montelukast Sodium Market size was valued at around USD 670.7 million in 2023 and is estimated to grow at 11.4% CAGR from 2024 to 2032. Montelukast sodium is a medication primarily used for the treatment of asthma and allergic rhinitis. It belongs to a class of drugs known as leukotriene receptor antagonists, work by blocking the action of leukotrienes, substances in the body that contribute to inflammation, bronchoconstriction and other symptoms associated with asthma and allergies.
 

The increasing prevalence of respiratory diseases includes asthma, allergic rhinitis serves as a substantial impetus for market growth. For instance, according to the World Health Organization (WHO), in 2019, asthma impacted approximately 262 million individuals worldwide and also led to 455,000 deaths during the same period. Thus, this underscores the need for effective pharmaceutical interventions such as montelukast sodium, plays a crucial role in managing conditions such as asthma and allergic rhinitis, thereby alleviating symptoms, improving quality of life, and potentially reducing mortality rates associated with these respiratory diseases. Furthermore, advancements in drug delivery and growing awareness and diagnosis are the promoting factors fostering the growth of the market.

Montelukast Sodium Market Trends

Advancements in drug delivery have revolutionized the landscape of pharmaceuticals, offering novel opportunities to enhance the efficacy, safety, and patient experience of various medications. This is particularly pertinent in the realm of respiratory medicine, for conditions such as asthma and allergic rhinitis present significant therapeutic challenges. Among the key medications used in managing these respiratory disorders is montelukast sodium, a leukotriene receptor antagonist known for its anti-inflammatory properties.
 

• Innovative drug delivery technologies can improve the absorption and bioavailability of montelukast sodium, ensuring that a higher percentage of the medication reaches the target site in the body, leading to improved therapeutic outcomes.
   
• Novel drug delivery systems such as extended-release formulations or convenient dosage forms can enhance patient convenience and compliance by reducing the frequency of dosing or eliminating the need for water for administration.
   
• Similarly, advanced drug delivery technologies can help to mitigate the potential side effects associated with montelukast sodium by optimizing drug release kinetics, reducing dose variability, and minimizing exposure to non-target tissues. Thereby escalating the growth of the market.
   

Montelukast Sodium Market Analysis

Based on product type, the market is divided into montelukast sodium amorphous and montelukast sodium crystalline. The montelukast sodium amorphous segment accounted for USD 387.6 million in 2023.
 

• Amorphous forms of drugs often exhibit higher solubility than their crystalline counterparts. This increased solubility can lead to faster dissolution and potentially improved bioavailability, the drug can be absorbed more readily into the bloodstream.
   
• This forms may have better stability under certain conditions such as in the presence of moisture or at higher temperatures, compared to crystalline forms. This improved stability can contribute to longer shelf life and better storage characteristics.
   
• Further, amorphous forms may provide greater flexibility in dosing options due to their enhanced solubility and potentially improved bioavailability. This could allow for the development of alternative dosage forms or strengths to better meet patient needs. Thus, driving the growth of the market.
   

Based on dosage form, the montelukast sodium market is divided into tablets and oral solutions. The tablets segment is estimated to account for USD 985.4 million by the end of 2032.
 

• Tablets are easy to administer and convenient for patients to take, as they can be swallowed whole with water or broken into smaller pieces if necessary.
   
• Montelukast sodium tablets offer accurate dosing and extended stability, ensuring patients receive consistent medication levels and longer-lasting efficacy compared to liquid or suspension formulations.
   
• Further, tablet formulations of montelukast sodium are often cost-effective compared to other dosage forms, making them accessible to a wider range of patients. Thus, propelling the growth of the market.
   

Based on application, the montelukast sodium market is bifurcated into asthma, allergic rhinitis, urticaria, and other applications. The asthma segment accounted for USD 262.9 million in 2023.
 

• Montelukast sodium acts as a leukotriene receptor antagonist, helping to reduce inflammation in the airways. By blocking the action of leukotrienes, it helps to decrease airway inflammation, a key component of asthma.
   
• It can be used as a preventive treatment for asthma particularly in individuals who have persistent asthma symptoms despite using other medications such as inhaled corticosteroids. It can help reduce the frequency and severity of asthma attacks, improving overall asthma control.
   
• Thus, such aforementioned factors are expected to augment the segmental growth.
   

Based on distribution channel, the montelukast sodium market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a market size of USD 277.7 million in the year 2023.
 

• Hospital pharmacies manage formularies, a lists of medications approved for use within the institution. By including montelukast sodium on the formulary, hospitals can ensure consistent availability of the medication for patients who require it.
   
• Hospital pharmacists have specialized knowledge and expertise in medication management including dosing, drug interactions, and adverse effects. They can ensure appropriate prescribing and monitoring of montelukast sodium for patients with asthma or other respiratory conditions.
   
• Therefore, hospital pharmacists also play a key role in patient education and counseling regarding medication use, including montelukast sodium. They can provide information about proper administration, potential side effects, and the importance of adherence to therapy. Thus, such factors are expected to escalate the growth of the market.
   

The U.S. montelukast sodium market is anticipated to grow at CAGR of 11.1% during the analysis timeframe.
 

• The U.S. has a highly developed healthcare infrastructure with advanced medical facilities and a robust pharmaceutical industry. This infrastructure facilitates the production, distribution, and access to montelukast sodium for patients across the country.
   
• The country has a significant prevalence of asthma. For instance, according to the Asthma and Allergy Foundation of America, in 2021 reported that 38.7% of children aged 18 and younger experienced one or more asthma attacks. Among children under the age of 5 with asthma, approximately 63.1% encountered such attacks during the same period. Additionally, 39.6% of adults aged 18 and older with asthma also reported experiencing one or more asthma attacks in the year.
   

The UK is anticipated to witness robust growth in the global montelukast sodium market.
 

• The UK's Medicines and Healthcare products Regulatory Agency (MHRA) upholds rigorous standards for the approval and regulation of pharmaceutical products, including montelukast sodium. This ensures the safety, efficacy, and quality of medications available in the UK market.
   
• The country is home to a wealth of clinical expertise in respiratory medicine, with skilled healthcare professionals specializing in conditions such as asthma and allergic rhinitis. This expertise ensures that montelukast sodium is prescribed and managed appropriately for patients.
   

Japan montelukast sodium market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan's highly advanced healthcare system coupled with universal health coverage, ensures access to medical services for its entire population including affordable medications like montelukast sodium. The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan upholds rigorous standards for approving and monitoring pharmaceutical products, ensuring their safety and efficacy.
   

The montelukast sodium market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia's significant healthcare infrastructure investment, evidenced by the establishment of hospitals, clinics, and specialized centers, widens access to medical services, including respiratory diseases testing, which is estimated to reach USD 26 billion by 2032, and treatment, in addition to medications such as montelukast sodium.
   
• There is a growing awareness of respiratory diseases such as asthma and allergic rhinitis in Saudi Arabia. This increased awareness encourages individuals to seek medical treatment, leading to higher demand for medications such as montelukast sodium.
   

Montelukast Sodium Market Share

The montelukast sodium industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Montelukast Sodium Market Companies

Some of the eminent market participants operating in the montelukast sodium industry include:

• Apotex Inc.                                 
• Cipla Limited          
• Dr. Reddy’s Laboratories Ltd.                            
• Intas Pharmaceuticals Ltd                                
• Merck & Co., Inc.                                   
• Morepen Laboratories Limited                                     
• Mylan N.V.                                  
• Sandoz AG                                  
• Sanofi                              
• Sun Pharma Industries Limited.                                  
• Teva Pharmaceutical Industries Limited   

Montelukast Sodium Industry News:

• In January 2023, Sun Pharmaceutical Industries Limited announced the acquisition of U.S.-based Concert Pharmaceuticals, a company known for developing innovative drugs. This strategic move bolstered Sun Pharma's portfolio and research capabilities, enhancing its position in the medications industry.
   

The montelukast sodium market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Montelukast sodium amorphous
• Montelukast sodium crystalline

Market, By Dosage Form

• Tablets         
• Oral solutions         

Market, By Application

• Asthma        
• Allergic rhinitis        
• Urticaria
• Other applications

Market, By Distribution Channel

• Hospital pharmacies          
• Retail pharmacies             
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa